Search

Your search keyword '"Lee, Kyung-Hun"' showing total 1,151 results
Start Over Author "Lee, Kyung-Hun"
1,151 results on '"Lee, Kyung-Hun"'

203. Abstract CT234: VASTUS - a phase 1b/2a basket trial of a new PARP inhibitor, IDX-1197, including PARP inhibitor resistant cohort

Author

Lee, Kyung-Hun, primary, Min, Ahrum, additional, Ahn, Hee Kyung, additional, Lee, Keun Seok, additional, Moon, Yong Wha, additional, Kim, Seung Tae, additional, Kim, Jeong Eun, additional, Sohn, Joo Hyuk, additional, Kim, Il Hwan, additional, Bae, Woo Kyun, additional, Lee, Myong Jae, additional, Roh, Eun-Jihn, additional, Ock, Chan-Young, additional, Lee, Won Sik, additional, and Im, Seock-Ah, additional

Published
2021
Full Text
View/download PDF

207. Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial.

Author

Ettl, Johannes, primary, Rugo, Hope S., additional, Hurvitz, Sara A., additional, Martin, Miguel, additional, Roche, Henri, additional, Lee, Kyung-Hun, additional, Goodwin, Annabel, additional, Usari, Tiziana, additional, Lanzalone, Silvana, additional, Guenzel, Carolin, additional, Blum, Joanne Lorraine, additional, and Litton, Jennifer Keating, additional

Published
2021
Full Text
View/download PDF

208. Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.

Author

Litton, Jennifer Keating, primary, Ettl, Johannes, additional, Hurvitz, Sara A., additional, Martin, Miguel, additional, Roche, Henri, additional, Lee, Kyung-Hun, additional, Goodwin, Annabel, additional, Usari, Tiziana, additional, Lanzalone, Silvana, additional, Guenzel, Carolin, additional, Blum, Joanne Lorraine, additional, and Rugo, Hope S., additional

Published
2021
Full Text
View/download PDF

210. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR

Author

Lim, Yoojoo, primary, Kim, Sheehyun, additional, Kang, Jun-Kyu, additional, Kim, Hwang-Phill, additional, Jang, Hoon, additional, Han, Hyojun, additional, Kim, Hyoki, additional, Kim, Min Jung, additional, Lee, Kyung-Hun, additional, Ryoo, Seung-Bum, additional, Park, Ji Won, additional, Jeong, Seung-Yong, additional, Park, Kyu Joo, additional, Kang, Gyeong Hoon, additional, Han, Sae-Won, additional, and Kim, Tae-You, additional

Published
2021
Full Text
View/download PDF

213. Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib

Author

Lee, Dae-Won, primary, Cho, Eun Ju, additional, Lee, Jeong-Hoon, additional, Yu, Su Jong, additional, Kim, Yoon Jun, additional, Yoon, Jung-Hwan, additional, Kim, Tae-Yong, additional, Han, Sae-Won, additional, Oh, Do-Youn, additional, Im, Seock-Ah, additional, Kim, Tae-You, additional, Lee, Youngeun, additional, Kim, Haeryoung, additional, and Lee, Kyung-Hun, additional

Published
2021
Full Text
View/download PDF

214. The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer

Author

Kim, Jin Won, primary, Lee, Kyung‐Hun, additional, Kim, Ji‐Won, additional, Suh, Koung Jin, additional, Nam, Ah‐Rong, additional, Bang, Ju‐Hee, additional, Jin, Mei Hua, additional, Oh, Kyoung‐Seok, additional, Kim, Jae‐Min, additional, Kim, Tae‐Yong, additional, and Oh, Do‐Youn, additional

Published
2021
Full Text
View/download PDF

216. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Author

Kudo, Masatoshi, primary, Lim, Ho Yeong, additional, Cheng, Ann-Lii, additional, Chao, Yee, additional, Yau, Thomas, additional, Ogasawara, Sadahisa, additional, Kurosaki, Masayuki, additional, Morimoto, Naoki, additional, Ohkawa, Kazuyoshi, additional, Yamashita, Tatsuya, additional, Lee, Kyung-Hun, additional, Chen, Erluo, additional, Siegel, Abby B., additional, and Ryoo, Baek-Yeol, additional

Published
2021
Full Text
View/download PDF

218. RANTES Polymorphisms and the Risk of Graft-versus-Host Disease in Human Leukocyte Antigen-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation

Author

Shin, Dong-Yeop, Kim, Inho, Kim, Jin Hee, Lee, Yun-Gyoo, Kang, Eun Joo, Cho, Hyeon Jin, Lee, Kyung-Hun, Kim, Hye Jin, Park, Eun-Hee, Lee, Jong-Eun, Bae, Ji-Yeon, See, Cha Ja, Yoon, Sung-Soo, Park, Sung Sup, Han, Kyou-Sup, Park, Myoung Hee, Hong, Yun-Chul, Park, Seonyang, and Kim, Byoung Kook

Published
2013
Full Text
View/download PDF

220. Study on elastic-plastic behaviour of inclusions in cold drawn wire by using reverse analysis and nanoindentation test

Author

Lee Kyung-Hun, Lee Jung-Min, Ji Se-In, Kim Jae-Hong, Ko Dae-Cheol, and Kim Byung-Min

Subjects
Engineering (General). Civil engineering (General), TA1-2040
Abstract

The purpose of this study is to investigate the elastic-plastic behavior of inclusions, i.e. SiO2 particles, in cold drawn wire using reverse analysis and nanoindentation test. First, the nanoindentation tests were performed to obtain indentation load P – penetration depth h curves. Second, the reverse analysis which is consisted of various dimensionless functions including change in E∗/σr, Wp/Wt and n was used to extract the elastic-plastic properties of the indented inclusions and metals from indentation responses. To verify the accuracy of calculated properties, uniaxial tensile tests were performed for different materials which are AISI 1045 and AISI 1080. Results (E, σy, n) of tensile tests for each material were also compared with those of nanoindentation tests.

Published
2015
Full Text
View/download PDF

221. Probability assessment of mechanical trimming using hot half-trimming in hot stamping process

Author

Shin Jun-Ho, Lee Kyung-Hun, Kim Byung-Min, and Ko Dae-Cheol

Subjects
Engineering (General). Civil engineering (General), TA1-2040
Abstract

The objective of this study is to investigate the probability of mechanical trimming using hot half-trimming in actual hot stamping process. Hot half-trimmed part can be inaccurately positioned on mechanical trimming die by relatively low accuracy of automatic transferring system or manual way, leading to the change of clearance in mechanical trimming. Taking into account this position error, a suitable operation window for trimming of flat and inclined part was constructed by FE-simulation and then was verified by experiment. It was determined from the operation window that effective mechanical trimming for both flat and inclined part can be performed successfully with hot half-trimming depth of 1.0 mm in hot half-trimming and clearance between 0.1 mm and 0.124 mm in subsequent mechanical trimming, without regard to position error.

Published
2015
Full Text
View/download PDF

228. Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial

Author

Litton, Jennifer K., primary, Hurvitz, Sara A., additional, Mina, Lida A., additional, Rugo, Hope S., additional, Lee, Kyung-Hun, additional, Gonçalves, Anthony, additional, Diab, Sami, additional, Woodward, Natasha, additional, Goodwin, Annabel, additional, Yerushalmi, Rinat, additional, Roché, Henri, additional, Im, Young-Hyuck, additional, Eiermann, Wolfgang, additional, Quek, Ruben G., additional, Usari, Tiziana, additional, Lanzalone, Silvana, additional, Czibere, Akos, additional, Blum, Joanne L., additional, Martin, Miguel, additional, and Ettl, Johannes, additional

Published
2020
Full Text
View/download PDF

229. Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)

Author

Zhu, Andrew X., primary, Guan, Yinghui, additional, Abbas, Alexander R., additional, Koeppen, Hartmut, additional, Lu, Shan, additional, Hsu, Chih-Hung, additional, Lee, Kyung-Hun, additional, Lee, Michael S., additional, He, Aiwu Ruth, additional, Mahipal, Amit, additional, Ding, Beiying, additional, Spahn, Jessica, additional, Verret, Wendy, additional, Ryoo, Baek-Yeol, additional, and Wang, Yulei, additional

Published
2020
Full Text
View/download PDF

230. Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure

Author

Lee, Yun Bin, primary, Lee, Cheol-Hyung, additional, Kim, Minseok Albert, additional, Jang, Heejoon, additional, Oh, Hyunwoo, additional, Kim, Sun Woong, additional, Cho, Eun Ju, additional, Lee, Kyung-Hun, additional, Lee, Jeonghoon, additional, Yu, Su Jong, additional, Yoon, Jung-Hwan, additional, Kim, Tae-You, additional, and Kim, Yoon Jun, additional

Published
2020
Full Text
View/download PDF

231. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment

Author

Lee, Cheol-Hyung, primary, Lee, Yun Bin, additional, Kim, Minseok Albert, additional, Jang, Heejoon, additional, Oh, Hyunwoo, additional, Kim, Sun Woong, additional, Cho, Eun Ju, additional, Lee, Kyung-Hun, additional, Lee, Jeong-Hoon, additional, Yu, Su Jong, additional, Yoon, Jung-Hwan, additional, Kim, Tae-You, additional, and Kim, Yoon Jun, additional

Published
2020
Full Text
View/download PDF

233. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Author

Desai, Jayesh, primary, Deva, Sanjeev, additional, Lee, Jong Seok, additional, Lin, Chia-Chi, additional, Yen, Chia-Jui, additional, Chao, Yee, additional, Keam, Bhumsuk, additional, Jameson, Michael, additional, Hou, Ming-Mo, additional, Kang, Yoon-Koo, additional, Markman, Ben, additional, Lu, Chang-Hsien, additional, Rau, Kun-Ming, additional, Lee, Kyung-Hun, additional, Horvath, Lisa, additional, Friedlander, Michael, additional, Hill, Andrew, additional, Sandhu, Shahneen, additional, Barlow, Paula, additional, Wu, Chi-Yuan, additional, Zhang, Yun, additional, Liang, Liang, additional, Wu, John, additional, Paton, Virginia, additional, and Millward, Michael, additional

Published
2020
Full Text
View/download PDF

234. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Author

Lee, Michael S, primary, Ryoo, Baek-Yeol, additional, Hsu, Chih-Hung, additional, Numata, Kazushi, additional, Stein, Stacey, additional, Verret, Wendy, additional, Hack, Stephen P, additional, Spahn, Jessica, additional, Liu, Bo, additional, Abdullah, Heba, additional, Wang, Yulei, additional, He, Aiwu Ruth, additional, Lee, Kyung-Hun, additional, Bang, Y-J, additional, Bendell, J, additional, Chao, Y, additional, Chen, J-S, additional, Chung, H C, additional, Davis, S L, additional, Dev, A, additional, Gane, E, additional, George, B, additional, He, A R, additional, Hochster, H, additional, Hsu, C-H, additional, Ikeda, M, additional, Lee, J, additional, Lee, M, additional, Mahipal, A, additional, Manji, G, additional, Morimoto, M, additional, Numata, K, additional, Pishvaian, M, additional, Qin, S, additional, Ryan, D, additional, Ryoo, B-Y, additional, Sasahira, N, additional, Stein, S, additional, Strickler, J, additional, and Tebbutt, N, additional

Published
2020
Full Text
View/download PDF

235. Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).

Author

Hsu, Chih-Hung, primary, Lu, Shan, additional, Abbas, Alex, additional, Guan, Yinghui, additional, Zhu, Andrew X., additional, Aleshin, Alexey, additional, Lee, Kyung-Hun, additional, Lee, Michael Sangmin, additional, Mahipal, Amit, additional, Ryoo, Baek-Yeol, additional, Ding, Beiying, additional, Spahn, Jessica, additional, Verret, Wendy, additional, He, Aiwu Ruth, additional, and Wang, Yulei, additional

Published
2020
Full Text
View/download PDF

236. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).

Author

Oh, Do-Youn, primary, Lee, Kyung-Hun, additional, Lee, Dae-Won, additional, Kim, Tae Yong, additional, Bang, Ju-Hee, additional, Nam, Ah-Rong, additional, Lee, Young, additional, Zhang, Qu, additional, Rebelatto, Marlon, additional, Li, Weimin, additional, and Kim, Jin Won, additional

Published
2020
Full Text
View/download PDF

242. Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.

Author

Kudo, Masatoshi, primary, Lim, Ho Yeong, additional, Cheng, Ann-Lii, additional, Chao, Yee, additional, Yau, Thomas, additional, Ogasawara, Sadahisa, additional, Kurosaki, Masayuki, additional, Morimoto, Naoki, additional, Ohkawa, Kazuyoshi, additional, Yamashita, Tatsuya, additional, Lee, Kyung-Hun, additional, Chen, Erluo, additional, Siegel, Abby B., additional, and Ryoo, Baek-Yeol, additional

Published
2020
Full Text
View/download PDF

244. Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients

Author

Yang, Yaewon, primary, Min, Ahrum, additional, Lee, Kyung-Hun, additional, Ryu, Han Suk, additional, Kim, Tae-Yong, additional, Woo, Go-un, additional, Suh, Koung Jin, additional, Lee, Dae-Won, additional, Lee, Han-Byoel, additional, Moon, Hyeong-Gon, additional, Han, Wonshik, additional, Park, In Ae, additional, Noh, Dong-Young, additional, and Im, Seock-Ah, additional

Published
2020
Full Text
View/download PDF

248. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer

Author

Macarulla Mercadé, Teresa, primary, Chen, Li-Tzong, additional, Li, Chung-Pin, additional, Siveke, Jens T., additional, Cunningham, David, additional, Bodoky, György, additional, Blanc, Jean-Frédéric, additional, Lee, Kyung-Hun, additional, Dean, Andrew, additional, Belanger, Bruce, additional, and Wang-Gillam, Andrea, additional

Published
2020
Full Text
View/download PDF

249. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.

Author

Tan, Ryan Shea Ying Cong, Ong, Whee Sze, Lee, Kyung-Hun, Lim, Abner Herbert, Park, Seri, Park, Yeon Hee, Lin, Ching-Hung, Lu, Yen-Shen, Ono, Makiko, Ueno, Takayuki, Naito, Yoichi, Onishi, Tatsuya, Lim, Geok-Hoon, Tan, Su-Ming, Lee, Han-Byoel, Ryu, Han Suk, Han, Wonshik, Tan, Veronique Kiak Mien, Wong, Fuh-Yong, and Im, Seock-Ah

Subjects
SURVIVAL rate, BREAST cancer, COHORT analysis, HORMONE receptors, IN situ hybridization
Abstract

Background: HER2-low breast cancer (BC) is currently an area of active interest. This study evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-metastatic breast cancer (BC).Methods: Patients with HER2-negative non-metastatic BC from 6 centres within the Asian Breast Cancer Cooperative Group (ABCCG) (n = 28,280) were analysed. HER2-low was defined as immunohistochemistry (IHC) 1+ or 2+ and in situ hybridization non-amplified (ISH-) and HER2-zero as IHC 0. Relapse-free survival (RFS) and overall survival (OS) by hormone receptor status and HER2 IHC 0, 1+ and 2+ ISH- status were the main outcomes. A combined TCGA-BRCA and METABRIC cohort (n = 1967) was also analysed to explore the association between HER2 expression, ERBB2 copy number variation (CNV) status and RFS.Results: ABCCG cohort median follow-up was 6.6 years; there were 12,260 (43.4%) HER2-low BC and 16,020 (56.6%) HER2-zero BC. The outcomes were better in HER2-low BC than in HER2-zero BC (RFS: centre-adjusted hazard ratio (HR) 0.88, 95% CI 0.82-0.93, P < 0.001; OS: centre-adjusted HR 0.82, 95% CI 0.76-0.89, P < 0.001). On multivariable analysis, HER2-low status was prognostic (RFS: HR 0.90, 95% CI 0.85-0.96, P = 0.002; OS: HR 0.86, 95% CI 0.79-0.93, P < 0.001). These differences remained significant in hormone receptor-positive tumours and for OS in hormone receptor-negative tumours. Superior outcomes were observed for HER2 IHC1+ BC versus HER2-zero BC (RFS: HR 0.89, 95% CI 0.83-0.96, P = 0.001; OS: HR 0.85, 95% CI 0.78-0.93, P = 0.001). No significant differences were seen between HER2 IHC2+ ISH- and HER2-zero BCs. In the TCGA-BRCA and METABRIC cohorts, ERBB2 CNV status was an independent RFS prognostic factor (neutral versus non-neutral HR 0.71, 95% CI 0.59-0.86, P < 0.001); no differences in RFS by ERBB2 mRNA expression levels were found.Conclusions: HER2-low BC had a superior prognosis compared to HER2-zero BC in the non-metastatic setting, though absolute differences were modest and driven by HER2 IHC 1+ BC. ERBB2 CNV merits further investigation in HER2-negative BC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

250. Psychiatric symptoms mediate the effect of resilience on health‐related quality of life in patients with breast cancer: Longitudinal examination.

Author

Lee, Sungwon, Jung, Saim, Jung, Sanghyup, Moon, Jung Yoon, Oh, Gyu Han, Yeom, Chan‐Woo, Son, Kyung‐Lak, Lee, Kwang‐Min, Kim, Won‐Hyoung, Jung, Dooyoung, Kim, Tae‐Yong, Im, Seock‐Ah, Lee, Kyung‐Hun, Shim, Eun‐Jung, and Hahm, Bong‐Jin

Subjects
QUALITY of life, BREAST cancer, CANCER patients, PSYCHOLOGICAL resilience, NEOADJUVANT chemotherapy, MENTAL depression
Abstract

Objective: Patients with breast cancer receiving neoadjuvant chemotherapy are at increased risk of poor health‐related quality of life (HRQOL). This study examined clinical caseness on depression and anxiety mediate the relationship between resilience and HRQOL in patients with breast cancer. Methods: A total of 193 patients with breast cancer undergoing neoadjuvant chemotherapy completed questionnaires including the Connor–Davidson Resilience Scale, Hospital Anxiety and Depression Scale (HADS), and Functional Assessment of Cancer Therapy‐Breast before the first session (T0), before the start of the last session (T1), and 6 months after the end (T2) of chemotherapy. Mediation analyses using a bootstrapping method was performed. Results: The indirect effect (IE) through T1 depression was significant (IE through depression = 0.043, 95% confidence interval [CI] [0.002–0.090]), while IE through T1 anxiety was not significant (IE through anxiety = 0.037, 95% CI [−0.010–0.097]) in the association between T0 resilience and T2 HRQOL. Conclusions: Clinical caseness on HADS depression subscale during chemotherapy was a mediating factor of the relationship between resilience before chemotherapy and HRQOL after chemotherapy in patients with breast cancer receiving neoadjuvant chemotherapy. Depression during chemotherapy in patients with breast cancer may be a target symptom of screening and intervention to maintain the HRQOL after chemotherapy. Also, patients with low resilience are more likely to develop depression during chemotherapy, and clinicians should carefully monitor whether depression occurs in these patients with low resilience. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results